Observational studyBMC palliative care2026
Satisfaction with treatment decision-making and long-term experiences of life-prolonging treatments for metastatic castration-resistant prostate cancer.
Observational study in BMC palliative care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatments in the phase of metastatic castration-resistant prostate cancer (mCRPC) aim to prolong survival and reduce the symptom burden. The fast development of life-prolonging therapies makes treatment decision-making (TDM) complex, weighting survival against possible side-effects and quality of life, especially in a real-world context. This study aimed to describe satisfaction with TDM at start of the first, second and third line of life-prolonging treatment and to describe and compare long-term treatment experiences when receiving one or several lines of treatment in patients with mCRPC.
methodsA longitudinal observational study. Participants completed a study-specific questionnaire every three months for up to two years from the start of any first line of life-prolonging treatment after mCRPC. Satisfaction with TDM was measured at the start of each new treatment line while treatment experiences were measured using the first and last completed questionnaire of each participant. Medical data was obtained from medical records. Descriptive statistics were used to present data while inferential statistics were used for analysis of group comparisons and over time changes.
resultsA total of 122 participants (mean age 75.3 years) with an average follow-up time of 18.3 months were included. Satisfaction with TDM was generally high at the start of the first, second and third line of treatment, but lower regarding discussions on how treatment could affect their life situation. Treatment experiences were positive, yet there was a significant decrease from the first to the last follow-up in whether they would choose (p = 0.04) and recommend (p = 0.01) the same treatment to others. For participants who received one line of treatment, a significant decrease was found between the first and the last follow-up (p = 0.02), while no differences were found for those who received two or more lines.
conclusionsDespite high satisfaction with aspects of TDM and the treatment given it is important to discuss how the treatment can impact the patient's life situation. The slightly decreased satisfaction over time on the treatment received could reflect a possible need to strengthen communication between patients and healthcare professionals, shifting from a disease-centered perspective towards a more person-centered and palliative care approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.